Tumor angiogenesis in advanced stage ovarian carcinoma.
Tumor angiogenesis has been found to have prognostic significance in many tumor types for predicting an increased risk of metastasis. We assessed tumor vascularity in 43 cases of advanced stage (International Federation of Gynecologists and Obstetricians stages III and IV) ovarian cancer by using the highly specific endothelial cell marker CD34. Microvessel counts and stage were associated with disease-free survival and with overall survival by Kaplan-Meier analysis. The plots show that higher stage, higher average vessel count at 200x (200x avg) and 400x (400x avg) magnification and highest vessel count at 400x (400x high) magnification confer a worse prognosis for disease-free survival. Average vessel count of less than 16 (400x avg, P2 = 0.01) and less than 45 (200x avg, P2 = 0.026) suggested a better survival. Similarly, a high vessel count of less than 20 (400x high, P2 = 0.019) conferred a better survival as well. The plots suggest that higher stage, higher average vessel count at 200x and 400x, and highest vessel count at 200x and 400x show a trend to worse overall survival as well. With the Cox proportional hazards model, stage was the best predictor of overall survival, however, the average microvessel count at 400x was found to be the best predictor of disease-free survival. These results suggest that analysis of neovascularization in advanced stage ovarian cancer may be a useful prognostic factor.
Hollingsworth
H C
HC
Laboratory of Pathology and Biostatistics, National Cancer Institute, Bethesda, Maryland 20892, USA.
Kohn
E C
EC
Steinberg
S M
SM
Rothenberg
M L
ML
Merino
M J
MJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000032:analysis; D018952:Antigens, CD34; D014408:Biomarkers, Tumor; D002196:Capillaries / Q000737:chemistry / Q000473:pathology; D002277:Carcinoma / Q000098:blood supply* / Q000737:chemistry / Q000473:pathology; D002452:Cell Count; D018572:Disease-Free Survival; D004730:Endothelium, Vascular / Q000737:chemistry / Q000473:pathology; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000098:blood supply* / Q000737:chemistry / Q000473:pathology; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D016019:Survival Analysis
D015703:Antigens, CD; D018952:Antigens, CD34; D014408:Biomarkers, Tumor